NCT06583291Not yet recruitingEarly phase 1
iDAP Injection in the Treatment of Parkinson's Disease
A Single Center, Open-label Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Allogeneic Dopaminergic Neural Precursor Cell(iDAP) Injection in the Treatment of Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 4 Sept 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that iDAP has on Parkinson's disease (PD) patients.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 1 Sept 2024
- Start date
- 1 Oct 2024
- Primary completion date
- 1 Oct 2028
- Lead sponsor
- Anhui Provincial Hospital
- Diseases
- Parkinson disease
- NCT number
- NCT06583291
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 12
- From 1 Oct 2024 to the primary completion date, 1 Oct 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have previously undergone brain surgery;
- Past use of stem cell therapy or participation in stem cell clinical research;
Other illness
- Cognitive impairment;
- History of mental disorders;
- Patients with other serious systemic diseases;
- Past or current metastatic malignant tumors.
Who the study is looking for
- Ages between 45 and 75 years;
- Diagnosed to be Parkinson's disease patients according to MDS Parkinson's disease diagnostic criteria;
- Disease history 4-20 years;
- Hoehn and Yahr Stage 2-4;
- Stable dose of dopamine for more than 3 months;
- Improvement of MDS-UPDRS part III;
Age in the registry: 45 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.